Goldman Sachs Group Significantly Increases Stake in Evotec SE to 6.12%
EVO sits 21% above its 52-week low of $2.84 on light trading volume (0.1× avg).
Summary
Goldman Sachs Group reported increasing its total stake in Evotec SE to 6.12% through instruments, signaling increased institutional interest, while MAK Capital also raised its holdings.
Key Events · Ownership and Investor Activity · EVO
-
Goldman Sachs Increases Holdings
The Goldman Sachs Group, Inc. reported increasing its total stake in Evotec SE to 6.12% as of January 13, 2026, primarily through instruments. This represents a 2.44% increase from its position on January 9, valued at approximately $14.89 million.
-
MAK Capital Increases Holdings
Michael Kaufman and MAK Capital Fund LP increased their combined stake in Evotec SE to 5.17% as of January 9, 2026, primarily through direct shareholdings. This is a net increase of 0.14% from their previous position, valued at approximately $0.85 million.
-
Prior Goldman Sachs Reduction
On January 9, 2026, Goldman Sachs had reported a temporary reduction in its total stake to 3.68% from a previous 5.27%, valued at approximately $8.66 million.
Analysis · EVO · Life Sciences
The filing indicates a notable increase in institutional ownership for Evotec SE. The Goldman Sachs Group, Inc. reported a significant increase in its total stake to 6.12% as of January 13, 2026, primarily through instruments. This latest move represents a substantial acquisition, following a temporary reduction earlier in January, and suggests renewed and stronger institutional confidence in the company. Additionally, Michael Kaufman and MAK Capital Fund LP also increased their combined stake to 5.17% on January 9, further contributing to a positive investor sentiment regarding the company's ownership structure.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVO was trading at $3.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.84 to $4.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.